The following is an edited excerpt. 

The U.S. Supreme Court decision on June 13, 2013 to uphold patent protections for genetic material that has been changed in the laboratory but invalidate patents for purely natural DNA may seem like a partial setback for the biotech industry, but experts said it isn’t: the industry has already moved on.

Read the full story here: As top court invalidates some gene patents, biotech has moved on